PUBLISHER: Orion Market Research | PRODUCT CODE: 1123343
PUBLISHER: Orion Market Research | PRODUCT CODE: 1123343
Global Ischemic Heart Disease Market Research By Disease Type (Angina, Myocardial Infarction and Ischemic Stroke), By Diagnosis Method (Electrocardiogram (ECG), Echocardiogram, Chest X-Ray, Cardiac Catheterization and Coronary Angiogram), and By Treatment (Medication and Surgery) Forecast Period 2021-2027
The global ischemic heart disease market is growing at a considerable CAGR of 4.7% during the forecast period. Increasing pervasiveness of cardiovascular diseases among people across the globe is one of the prime factors affecting and driving the market. Increasing population having high cholesterol along with obesity, and accessibility of effective surgical treatments is also estimated to be the prime factors that are contributing significantly towards the growth of the market. However, rising uncertainty related with reimbursement policy along with high cost involvement are some major factors constraints that are hindering the growth of the global ischemic heart disease market across the globe.
However, government initiative along with funding and rising awareness towards various heart diseases is one of the key factors that are creating opportunities for the market. New product launches in the market are likely to drive the growth of the global ischemic heart disease market. For instance, In June 2020, AstraZeneca Brilinta (ticagrelor) had received approval and clearance in the US in order to decrease the risk factor related with first heart attack or patient having high risk with coronary artery disease (CAD) which is considered to be the most common type of heart disease. This approval was being received by the company on the basis of the Phase 3 EMIS trial. The trial had given the positive result related to reduction in heart attack and stroke.
Impact of COVID-19 on the Global Ischemic Heart Disease Market
The global ischemic heart disease market is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies had disrupted the manufacturing and transportation activities. There were disruptions in ischemic heart disease testing across the globe. All the activities related with ischemic heart disease were being reduced from disease diagnosis till treatment due to COVID-19 pandemic.
Segmental Outlook
The market is segmented based on a disease type, diagnosis method and treatment. Based on disease type, the market is segmented into angina, myocardial infarction and ischemic stroke. By diagnosis method, the market is segmented into electrocardiogram (ECG), echocardiogram, chest x-ray, cardiac catheterization and coronary angiogram. Further, by treatment, market is segmented into medication and surgery.
Global Ischemic Heart Disease Market Share by Disease Type 2020 (%)
Global Ischemic Heart Disease Market Share by Disease Type
Based on the disease type, angina hold a significant share in the market. Angina is considered as the type of heart problem in which the heart muscle does not get sufficient oxygen rich blood and it causes a chest pain. Additionally, the sense of discomfort can also be felt due to it in neck, jaw, back or even in shoulders and arms. Angina can also signify the symptoms related with Coronary Microvascular Disease (MVD).
Regional Outlooks
The global ischemic heart disease market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in 2020 in the global ischemic heart disease market. Some factors that are boosting the market growth in North America are growing pervasiveness of cardiovascular diseases, leading manufactures and players present mobility devices in the region. Additionally, favorable reimbursement along with increasing awareness related with heart disease is other factors that are promoting the growth of the market.
Global Ischemic Heart Disease Market, by Region 2021-2027
Global Ischemic Heart Disease Market, by Region
Asia-Pacific will have Considerable Growth in the Global Ischemic Heart Disease Market
Asia-Pacific region is expected to witness significant growth opportunities for the market. Increasing awareness towards coronary artery disease (CAD) along with changing lifestyle pattern that leads to unhealthy diet among people in emerging economies of the region are likely to drive the growth of the regional market. Further due to health and medical attention availability, rising health care expenditure along with increasing pervasiveness of heart diseases and strokes in India, China and South Korea are also some of the factors that are affecting and impacting the growth in this market.
Market Player Outlook
Key players of the global ischemic heart disease market are Abbott, AstraZeneca, Boston Scientific Corp., Koninklijke Philips N.V, and Sanofi among others. To survive in the market, these players adopt different marketing strategies such as product launches, collaboration and acquisition. For instance, in August 2020, Koninklijke Philips N.V that is one of the global providers of technology in healthcare sector had announced the acquisition of Intact vascular Inc. The acquired company is the US developers of medical devices and through this acquisition it will enhance the portfolio of Koninklijke Philips N.V in image-guided therapy which will support in patient's treatment with Peripheral Artery Disease (PAD).
In November 2020, Stryker had set forth that it had completed the acquisition of wright medical group NV which is one of the medical device companies. Through this company can provide effective solution that will lead to better outcomes related with the health of patients.
In April 2019, Sanofi had received the acceptance and clearance from United States Food and Drug Administration (FDA) for praluent (Alirocumab). Praluent was prepared by collaboration between Sanofi along with Regeneron which is one of the biotechnology companies in order to decrease the risk related with heart attack, strong along with unstable angina.
The Report Covers
Market value data analysis of 2020 and forecast to 2027.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global ischemic heart disease market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where in the market.